United Price To Sales Ratio from 2010 to 2024
| UTHR Stock | USD 275.00 1.40 0.51% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 4.42141869 | Current Value 4.2 | Quarterly Volatility 260.76831845 |
Check United Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among United Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 55.9 M, Total Revenue of 2.4 B or Gross Profit of 2.2 B, as well as many indicators such as Price To Sales Ratio of 4.2, Dividend Yield of 0.0114 or PTB Ratio of 1.63. United financial statements analysis is a perfect complement when working with United Therapeutics Valuation or Volatility modules.
United | Price To Sales Ratio |
Latest United Therapeutics' Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of United Therapeutics over the last few years. Price to Sales Ratio is figured by comparing United Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on United Therapeutics sales, a figure that is much harder to manipulate than other United Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period. United Therapeutics' Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in United Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 4.70 X | 10 Years Trend |
|
Price To Sales Ratio |
| Timeline |
United Price To Sales Ratio Regression Statistics
| Arithmetic Mean | 71.63 | |
| Geometric Mean | 6.02 | |
| Coefficient Of Variation | 364.05 | |
| Mean Deviation | 125.68 | |
| Median | 4.42 | |
| Standard Deviation | 260.77 | |
| Sample Variance | 68,000 | |
| Range | 1K | |
| R-Value | (0.43) | |
| Mean Square Error | 59,569 | |
| R-Squared | 0.19 | |
| Significance | 0.11 | |
| Slope | (25.19) | |
| Total Sum of Squares | 952,002 |
United Price To Sales Ratio History
About United Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include United Therapeutics income statement, its balance sheet, and the statement of cash flows. United Therapeutics investors use historical funamental indicators, such as United Therapeutics's Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Although United Therapeutics investors may use each financial statement separately, they are all related. The changes in United Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on United Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on United Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in United Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 4.42 | 4.20 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.